GE HealthCare stock holds firm after Q2 beat

GE HealthCare stock is supported by a Q2 beat, a 3.6% post-earnings gain over the past month, and 2026 guidance that still calls for 3% to 4% organic growth.

GE HealthCare Technologies Inc. (US36266G1076) is trading on a mix of fresh earnings data and a month-long share gain of 3.6% after its second-quarter 2026 report. The latest figures show adjusted EPS of $1.13 on revenue of $5.29 billion, while the company kept 2026 organic revenue growth guidance at 3% to 4%.

Q2 numbers still drive the tape

According to a market note, GE HealthCare beat the consensus estimate for adjusted EPS by 8.7% and topped revenue expectations by 0.7% in the second quarter of 2026. The same report said total company orders rose 11.1% organically, and backlog reached a record $23.9 billion.

That combination matters because the company also reported $250 million of inflation tied to memory chips, oil and freight, yet still reaffirmed adjusted EPS guidance of $4.80 to $5.00 for 2026. Net income margin reached 10.6%, and cumulative operating cash flow was $458 million in the quarter, up from $344 million a year earlier.

What the market is pricing

Shares had a previous close of $93.48, with a day range of $91.18 to $93.21, 52-week trading between $74.51 and $94.80, and intraday market cap of $42.167 billion. The stock's 1-year target estimate on the quote page was $99.46, leaving the current quote inside the upper part of its annual range.

For investors, the key comparison is simple: revenue grew 5.7% year over year while adjusted EPS rose 6.6%, and both numbers stayed above consensus. The order book and guidance suggest the next move in the stock will still hinge on whether management converts that backlog into steadier segment execution, especially in Patient Care Solutions.

Ultrasound portfolio

GE HealthCare recently added three ultrasound systems to its Vivid cardiovascular portfolio at the European Society of Cardiology Congress 2026 in Munich, expanding a product line tied to cardiac imaging and workflow tools. The move adds another concrete growth lever for a company that already said Pharmaceutical Diagnostics revenue rose 15.6% to $843 million and Advanced Imaging Solutions revenue increased 7.9% to $3.77 billion in the second quarter.

Stock level and setup

The stock closed at $93.48 on the quote page, with a 52-week range of $74.51 to $94.80 and market cap of $42.75 billion shown on the same snapshot. GE HealthCare stock now sits close to the top of that band as the market weighs a record $23.9 billion backlog against full-year EPS guidance of $4.80 to $5.00.

More on GE HealthCare Technologies Inc.

Company: GE HealthCare Technologies Inc.

ISIN: US36266G1076

Ticker: GEHC

Exchange: Nasdaq

Sector / Industry: Healthcare / Health Information Services

Index membership: S&P 500

Market cap: $42.75 billion

Next earnings date: May 14, 2025